Berlin

• Investigation of 3 different doses of a newly developed vaginal ring releasing estriol for the treatment of vaginal atrophy - a placebo-cont … Ended
  2024-514302-31-00 4 2025-07-16 Vaginal atrophy
• A mono-centre, non-comparative clinical trial on the inhibition of ovulation with LNG POP (Levonorgestrel tablet) during three 28-day cycles … Ended
  2025-521236-12-00 4 2025-07-02 Investigation of ovulation inhibition after intentional IMP intake err
• A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors Ended
  2024-514745-10-00 1 2025-06-23 Melanoma (or) malignant melanoma Non-small cell lung cancer Head and n
• A trial to learn about how multiple doses of itraconazole change how AZD5004 moves throughout the body over time in healthy adults and how m … Ended
  2024-518467-35-00 3 2025-05-28 Not applicable, healthy volunteers
• A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of … Ended
  2024-517814-13-00 4 2025-04-30 Moderate to Severe Atopic Dermatitis
• A study in healthy people to test whether erythromycin influences the amount of BI 1291583 in the blood. Ended
  2024-515795-12-00 3 2025-04-29 Healthy volunteer trial
• An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab Ended
  2024-511840-22-00 3 2025-04-22 Inflammation
• Open-label basket study for safety and pharmacokinetics evaluation of INF904 in subjects with CSU or HS Ended
  2024-515615-22-00 4 2025-04-02 Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to
• A trial in healthy participants to examine the safety, tolerability, and pharmacokinetics of orally administered FT751 Ended
  2024-519998-19-00 1 2025-03-31 Inflammatory diseases
• A Phase I, Randomised, Investigator- and Participant-blinded, Placebo-Controlled, Study to Assess the Safety, Tolerability, and Pharmacodyna … Ended
  2024-519414-31-00 3 2025-03-28 Cardiorenal disease
• A clinical research study investigating how the body processes the new compound petrelintide in people with kidney problems Ended
  2024-518124-77-00 3 2025-03-26 Weight management
• TGD001 SAD study in healthy volunteers Ended
  2024-514931-63-00 1 2025-03-14 A Phase I randomized, double-blind, placebo-controlled study to assess
• Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended
  2024-510972-19-00 4 2025-03-13 Primary mediastinal large B-cell lymphoma (PMBCL)
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 Relapsed/Refractory Tumors
• A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 1 … Ended
  2024-512022-28-01 3 2025-03-12 Sepsis and Septic Shock
• Phase 2, randomized, double-blind, placebo-controlled study of IC0624 as first-line therapy in patients with active mild to moderate Hidrade … Ended
  2024-518180-35-00 4 2025-03-03 Hidradenitis Suppurativa
• A phase I/II trial of D,L-MEthadone and mFOLFOX6 in treatment of advanced colorectal cancer (MEFOX) Ended
  2024-519509-37-00 9 2025-02-25 Patients with advanced, histologically confirmed, metastatic colorecta
• A weight loss study evaluating subcutaneous treatment withAZD9550 and AZD6234 in combination, against placebo or each of the drugs alone Ended
  2024-516176-15-00 4 2025-02-24 Investigating obesity or overweight condition correlated to many co-mo
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• A Phase Ib, Multicentre, Randomised, Single-blind, Parallel-group, Placebo-controlled, Study to Characterise the Pharmacokinetics and Pharma … Ended
  2024-516474-30-00 3 2025-02-19 Asthma
• An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination wi … Ended
  2024-512670-10-00 9 2025-02-13 Unresectable or Metastatic Melanoma
• Phase 1 first-in-human, single and multiple dosing study of FB301 in healthy female subjects Ended
  2024-517539-38-00 1 2025-02-13 Women infertility
• A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adu … Ended
  2024-514213-35-00 3 2025-01-20 Asthma
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis

Showing 1,321–1,344 of 1,776 trials